Growing demand for sophisticated and personalized treatment options to cure liver metastasis is expected to boost the market.Rockville, MD, Dec. 10, 2024 (GLOBE NEWSWIRE) -- According to Fact.MR, a ...

The study highlights how EV-DNA packaging influences immune responses and its promise as a biomarker for assessing colorectal ...

MCCLEAN, VA, UNITED STATES, December 16, 2024 /EINPresswire / -- Perthera, the leader in AI-driven Precision Oncology Decision Support, has unveile ...

About Zetagen Therapeutics Founded in 2015, Zetagen Therapeutics is a private, clinical-stage, biopharmaceutical company ...

Specially packaged DNA secreted by tumor cells can trigger an immune response that inhibits the metastatic spread of the tumor to the liver, according to a study led by researchers at Weill Cornell ...

From detecting early disease to guiding treatment plans, clinicians are finding ctDNA testing increasingly important.

Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer - REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- ...

Patients with heavily pretreated microsatellite stable metastatic colorectal cancer (CRC) had survival benefits after using ...

Contrary to expectations, higher levels of this EV-DNA reduced liver metastasis risks in pancreatic and colorectal cancers.

On the morning of December 12, 2024 (UTC-6), at the Poster Spotlight Session "Novel HER2 Therapeutics" of the 47th San ...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver ...